<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000994</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 001</org_study_id>
    <secondary_id>10977</secondary_id>
    <nct_id>NCT00000994</nct_id>
  </id_info>
  <brief_title>A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma</brief_title>
  <official_title>A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine whether taking zidovudine (AZT) will change the natural course of HIV infection&#xD;
      in patients with AIDS-associated Kaposi's sarcoma (KS) and whether administering AZT at a&#xD;
      similar dose but at different intervals will reduce toxicity in a more manageable treatment&#xD;
      plan.&#xD;
&#xD;
      Patients infected with AIDS can benefit from therapy with an effective anti-AIDS virus agent.&#xD;
      AZT is a drug that is effective in inhibiting the effects of HIV infection. The study will&#xD;
      show whether toxicity of AZT can be reduced in a more manageable treatment plan, and whether&#xD;
      AZT therapy will delay the development of opportunistic infections and/or KS lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients infected with AIDS can benefit from therapy with an effective anti-AIDS virus agent.&#xD;
      AZT is a drug that is effective in inhibiting the effects of HIV infection. The study will&#xD;
      show whether toxicity of AZT can be reduced in a more manageable treatment plan, and whether&#xD;
      AZT therapy will delay the development of opportunistic infections and/or KS lesions.&#xD;
&#xD;
      Patients are divided into two treatment groups, the first receiving AZT for 5 doses a day,&#xD;
      and the second receiving AZT for 3 doses per day. A placebo group is divided into two to&#xD;
      match the two treatment groups. Study patients are stratified according to whether they have&#xD;
      (a) 10 or fewer cutaneous lesions without oral lesions or (b) more extensive cutaneous&#xD;
      lesions or oral lesions. Patients are seen on an outpatient basis weekly for the first 2&#xD;
      months, every other week for the next 2 months, and monthly thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">May 1990</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>240</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Acute treatment for mucocutaneous candidiasis, localized cutaneous herpes simplex, or&#xD;
             localized or disseminated zoster infections.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Blood transfusion for treatment of Grade 3 hemoglobin toxicity if the patient's&#xD;
             cardiovascular status is compromised or if the hemoglobin fails to show signs of&#xD;
             recovery following withdrawal from the study drug. Toxicity grades according to NIAID&#xD;
             Recommendations for Grading Acute and Subacute Toxic Effects (Adults).&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV-related, biopsy-proven Kaposi's sarcoma mucocutaneous lesions without&#xD;
             constitutional symptoms.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions will be excluded:&#xD;
&#xD;
          -  Symptomatic, visceral Kaposi's sarcoma.&#xD;
&#xD;
          -  Lymphedema.&#xD;
&#xD;
          -  HIV neurologic disease as determined by a standard neurologic examination and&#xD;
             neuropsychological questionnaire.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Aspirin or acetaminophen on a regular basis or for longer than 72 hours without&#xD;
             approval of investigator.&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
          -  Flurazepam.&#xD;
&#xD;
          -  Indomethacin.&#xD;
&#xD;
          -  Ranitidine.&#xD;
&#xD;
          -  Probenecid.&#xD;
&#xD;
          -  Drugs causing anemia, neutropenia, or significant risk of nephrotoxicity.&#xD;
&#xD;
          -  Prophylaxis or chronic suppression of herpes simplex.&#xD;
&#xD;
          -  Treatment of herpes simplex virus cutaneous disease more often than once a month for 5&#xD;
             - 7 days.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy for treatment of Kaposi's sarcoma lesions.&#xD;
&#xD;
        The following patients will be excluded from the study:&#xD;
&#xD;
          -  Patients with a history of any AIDS-defining opportunistic infection.&#xD;
&#xD;
          -  Patients with any of the following constitutional symptoms with no etiology&#xD;
             established:&#xD;
&#xD;
          -  Temperature more than 38 degrees and/or drenching night sweats for more than 1 month;&#xD;
             watery diarrhea for 2 or more weeks; weight loss of more than 10 percent.&#xD;
&#xD;
          -  Patients with a history of other systemic malignancies or lymphomas.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Systemic antineoplastic chemotherapy.&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Antiretroviral agents.&#xD;
&#xD;
          -  Immunomodulating agents.&#xD;
&#xD;
          -  Prophylaxis for Pneumocystis carinii pneumonia.&#xD;
&#xD;
          -  Prophylaxis for herpes simplex virus infections.&#xD;
&#xD;
          -  Any other experimental therapy.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Any experimental therapy.&#xD;
&#xD;
          -  Active substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentine FT</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California / San Diego Treatment Ctr</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>921036325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford at Kaiser / Kaiser Permanente Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Univ School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charity Hosp / Tulane Univ Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State Univ Med Ctr / Tulane Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard (Massachusetts Gen Hosp)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Veterans Administration / Mount Sinai Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY / Erie County Med Ctr at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hosp Ctr at Elmhurst / Mount Sinai Hosp</name>
      <address>
        <city>Elmhurst</city>
        <state>New York</state>
        <zip>11373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr / Peter Krueger Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hosp / New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mem Sloan - Kettering Cancer Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY / State Univ of New York</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chaisson RE, Fuchs E, Stanton DL, Quinn TC, Hendricksen C, Bartlett JG, Farzadegan H. Racial heterogeneity of HIV antigenemia in people with HIV infection. AIDS. 1991 Feb;5(2):177-80. doi: 10.1097/00002030-199102000-00007.</citation>
    <PMID>1903261</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Sarcoma, Kaposi</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

